

PTO/SB/08a/b (07-05)

ed for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete If Known**

Application Number	10/534,628
Filing Date	May 10, 2005
First Named Inventor	Nedjeljko Kujundzic
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	03818/0202874-US0

Sheet	1	of	21
-------	---	----	----

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
EP	AA*	US-4,328,334	05-04-1982	G. Kobrehel et al.	
EP	AB*	US-4,474,768	10-02-1984	G. M. Bright et al.	
EP	AC*	US-4,492,688	01-08-1985	Bright G. M.	
EP	AD*	US-6,852,702	02-08-2005	Kujundzic, et al.	
EP	AE*	US-6,872,707	03-29-2005	Marusic-Istuk, et al.	
EP	AF*	US 5,629,296	05-13-1997	Kujundzic et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
EP	BA	EP 0316 128	07-17-1981	G. M. Bright et al.		
EP	BB	FR-2,473,525	03-03-1993	G. S. Ambrieres		
EP	BC	BE 892,397	01-07-1982	Kobrehel et al.		
EP	BD	WO 2004/043984	05-27-2004	KUJUNDZIC, Nedjeljko et al.		✓
EP	BE	WO 2004/052904	06-24-2004	KUJUNDZIC, Nedjeljko et al.		✓
EP	BF	WO 97/35590	10-02-1997	Chris E. Platt		✓
EP	BG	EP 0657 464	10-30-1996	KUJUNDZIC, Nedjeljko et al.		✓
EP	BH	EP 0132 944	12-30-1986	G. M. Bright		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
EP	CA	McGuire [Antibiotics and Chemotherapy, vol II, no. 6 (6/1952) 281-283]	
EP	CB	P. Kurath et al., Experientia 27/4 (1971) 362	
EP	CC	S. E Djokic et al., Tetrahedron Letters, no. 17, 4/1967: 1645-1647	
EP	CD	R. S. Egan et al., J. Org. Chem. No. 17, vol. 39 (8/1974) 2492-2494	
EP	CE	P. Lugar et al., Journal of Crystal and Molecular Structure, vol. 9, no. 6 (12/1979) 329-338	
EP	CF	Journal of Antibiotics, vol. 46, no. 8 (1/1993) 1239-1245 (G. Kobrehel et al.)	
EP	CG	Azalides: synthesis and antibacterial activity of novel 9a-N-(N'-substituted carbamoyl and thiocarbamoyl) derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A; N Kujundzic et al., PLIVA, Research Institute, Eur J. Med Chem (1995) 30, 455-462	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Elli Peselev/	Date Considered	02/13/2007
--------------------	----------------	-----------------	------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/534,628-Conf. #8552
				Filing Date	October 5, 2005
				First Named Inventor	Nedjeljko Kujundzic
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	03818/0202874-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
EP	BA	WO/2002/068438		09-06-2002	Pliva D.D.		✓
EP	BB	WO/2002/12260		02-14-2002	Pfizer Products inc.		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Elli Poselev/	Date Considered	02/13/2007
-----------------------	----------------	--------------------	------------